AsthmaPANAMENCT02869958
Digital Action Plan for Asthma Attacks
A study testing Digital action plan for asthma exacerbations + Written action plan and Written action plan in people with Asthma, run by Assistance Publique - Hôpitaux de Paris at 2 sites in France.
Trial summary
It is recommended that patients with asthma owned a written action plan which must include the names, doses and dosing of the treatment they should take when acute respiratory symptoms occur. Current written action plans must be short to be readily used (1 page) and, therefore, cannot fit all acute situations. Read more about this study
- Who is it for?
- Ages 6 to 60 years
- Conditions the study is for
- Asthma
- What is being tested?
- Digital action plan for asthma exacerbations + Written action plan and Written action plan
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 280 participants
- Where
- 2 sitesFrance
- Study dates
- 3 Nov 2016to 29 Apr 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 60 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- children from 6 to 12 years or adults aged between 18 and 60 years
- typical asthma with medical diagnosis
- severe exacerbation (requiring ≥ 3 days of oral corticosteroids) during the previous 12 months
- Internet connexion through a private (patient's or parents' patient's if child) smartphone and/or a tablet computer
- no use of a written actin plan within the last 1 year
- agreement to have phone calls or email contacts during the 1 year follow-up of the study
- informed consent given, signed consent
- affiliation to a social security
Who cannot join
- atypical asthma: isolated cough, exercise respiratory discomfort
- other respiratory disease (cystic fibrosis, COPD, etc.)
- Severe heart disease (except high blood pressure)
- smoking > 15 pack-years
- asthma requiring regular oral corticosteroids treatment
- asthma requiring inhaled controller treatment administered via nebulizations performed at home
Show all 9Show fewer
- no health insurance coverage
- sister or brother already included in this study (applies only to children)
- pregnancy and breastfeeding
Trial locations and contacts
2 sites in 1 country.
France2 sites
Hôpital Privé Armand Brillard
Nogent-sur-Marne, 94130
MulticEnter French study coordinate by AP-HP
Paris, 75012
About this study
Official title: Digital Action Plan for Asthma Exacerbations (PANAME)
It is recommended that patients with asthma owned a written action plan which must include the names, doses and dosing of the treatment they should take when acute respiratory symptoms occur.
Current written action plans must be short to be readily used (1 page) and, therefore, cannot fit all acute situations. Moreover, they may not be available where and when required.
Read more
The investigators sought that a digital action plan, available through Smartphone or tablet computer connected to the internet, could adequately provide suitable action plans according to the severity of the described exacerbation, and would be more easily available when useful.
The aim of the study is to study the effect of the use of a digital action plan for asthma exacerbation, on the frequency of unscheduled medical contacts (phone calls, visits to physicians or to emergency departments, hospitalizations) in children and in adults with asthma. The investigators hypothesized that the use of the digital action plan could reduce avoidable unscheduled visits due to mild or moderate exacerbations that could successfully be managed by the patient or his/her caregivers.
Read the detailed description
Asthma is a frequent chronic disease (10% prevalence in children and 7% in adults) during which acute exacerbations can occur that require adequate treatment, usually by the patients and/or his/her caregivers. Despite action plan for asthma exacerbation being recommended by national and international guidelines, urgent medical contact and often Emergency Department visits remain frequent for asthma exacerbation.
Reasons for medical contact may be related to the inefficiency of the current Written Action Plan because of its stereotyped advice whatever the level of severity of the exacerbation, and because the patients might not have the paper with him/her where and when he/she needs it.
The investigators sought that new electronic technologies could solve these issues of inadequacy of content and availability of the Written Action Plan.
A program was built to provide sets of advices according to the severity of the exacerbation described by the patient using simple clinical descriptors included in the Global Initiative for Asthma (GINA), and weighted by the medication already used for the exacerbation. In this way the investigators feel that patients could be more confident in the appropriate treatment proposed by the algorithm. Second, the possibility to connect through portable electronic devices (Smartphone, tablet computer) make the action readily available as far as an internet connection is possible.
The Digital Action Plan is designed to treat asthma exacerbations of all levels of severity and advice to visit a doctor within few days or to go at once to an emergency department as appropriate as by the situation based on the patients' information. The investigators designed a randomized study to assess the effect of the Digital Action Plan on unscheduled urgent medical contacts (phone calls, visits to physicians or to emergency departments, hospitalizations) in children and in adults with asthma.
Methodology of the study A multicenter, controlled, randomized, open study, comparative on 2 parallel groups recruited in private practice and in hospitals within or outside the APHP consortium.
Both arms have the Written Action Plan respecting the current recommendations; the experimental arm has in addition the possibility to connect to the AppWeb to obtain advices from the Digital Action Plan.
The investigators hypothesized that the use of the digital action plan could reduce avoidable unscheduled visits due to mild or moderate exacerbations that could successfully be managed by the patient or his/her caregivers. In the long run, this kind of program could also become a tool for telemedicine Statistical analysis : about 80% of children and adult patients included will have a exacerbation during the follow-up year. The expected effect of the Digital Action Plan is a 20% (relative variation) decrease of the main outcome : in Written Action Plan group, frequency = 0.8, in Digital Action Plan group, frequency = 0.64 (20% i.e. 0.16 reduction of frequency). Moreover, the Written Action Plan has been shown to result in a 25% decrease of unscheduled visits for severe exacerbation (4); we therefore hypothesize that the supplemental reduction in unscheduled visits induced by the Digital Action Plan will be smaller than that of Written Action Plan despite the recording of moderate exacerbations in addition to severe exacerbations. . With this features, samples of N= 121 per group are necessary (80% power, bilateral alpha risk of 5%). With an expected attrition of about 15%, a total of 280 patients will be included. This target can be achieved with regard to the activity of participating centers.
Number of participating centers = 43
- Conditions
- Asthma
- Being tested
- Digital action plan for asthma exacerbations + Written action plan, Written action plan
- Keywords
- Asthma, Exacerbation, Treatment, Internet, Emergency care
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Digital action plan for asthma exacerbations + Written action planOther
Also called Digital action plan for asthma exacerbations
Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
Written action planOther
| Study group | Role | What they receive |
|---|---|---|
| 1: Written action plan | Active comparator | Written action plan Receives: Other: Written action plan |
| 2: Digital action plan | Experimental | Written action plan + Digital action plan for asthma exacerbations Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation Receives: Other: Digital action plan for asthma exacerbations + Written action plan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of visits or unscheduled medical contacts
Frequency of urgent medical recourses (composite criterion): visits or unscheduled medical contacts + Emergency Departments visits or hospitalizations, in both arms of randomization
Measured: during the 1 year follow-up
Emergency Departments visits or hospitalizations
Frequency of urgent medical recourses (composite criterion): visits or unscheduled medical contacts + Emergency Departments visits or hospitalizations, in both arms of randomization
Measured: during the 1 year follow-up
Secondary outcomes (10)
Adherence to the Digital Action Plan = number of moderate to severe exacerbations entered in the AppWeb with respect to all moderate to severe exacerbations reported
Measured: during the 1 year follow-up
Adherence to the Written Action Plan (number of times Written Action Plan was used with respect to all moderate to severe exacerbations)
Measured: during the 1 year follow-up
qualitative evaluation of the Digital Action Plan: descriptive study using a questionnaire filled out in the arm using the AppWeb
Measured: at 1 year
number of unscheduled visits or medical contacts during the 1 year follow-up
Measured: during the 1 year follow-up
number of visits in Emergency Departments
Measured: during the 1 year follow-up
number of hospitalizations (>6 hours)
Measured: during the 1 year follow-up
number of school or working days missed
Measured: during the 1 year follow-up
number of scheduled medical
Measured: during the 1 year follow-up
Cumulative dose (in mg/kg) of oral corticosteroids during the 1 year follow-up
Measured: during the 1 year follow-up
assessment of the level of asthma control (GINA criteria) by a phone call
Measured: every 3 months, during the 1 year follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2016 (estimated)
- Study start3 Nov 2016
- Primary completion29 Apr 2020
- Study completion29 Apr 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for AsthmaStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 280 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Nicole BEYDON, MD, Principal investigator, Assistance Publique - Hôpitaux de Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02869958
- Sponsor's protocol ID
- P140316
- Acronym
- PANAME
- Status last verified
- Dec 2020
- First submitted
- 5 Jul 2016
- Last updated
- 4 Dec 2020
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Beydon N, Taille C, Corvol H, Valcke J, Portal JJ, Plantier L, Mangiapan G, Perisson C, Aubertin G, Hadchouel A, Briend G, Guilleminault L, Neukirch C, Cros P, Appere de Vecchi C, Mahut B, Vicaut E, Delclaux C. Digital Action Plan (Web App) for Managing Asthma Exacerbations: Randomized Controlled Trial. J Med Internet Res. 2023 Jun 29;25:e41490. doi: 10.2196/41490.
PubMed 37255277
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Digital Action Plan for Asthma Exacerbations (PANAME)
- ClinicalTrials.gov ID
- NCT02869958
- Acronym / sponsor ID
- PANAME / P140316
- Conditions
- Asthma
- Keywords
- Asthma, Exacerbation, Treatment, Internet, Emergency care
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 280 participants (actual)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 3 Nov 2016 (actual)
- Primary completion
- 29 Apr 2020 (actual)
- Study completion
- 29 Apr 2020 (actual)
- First posted
- 17 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is recommended that patients with asthma owned a written action plan which must include the names, doses and dosing of the treatment they should take when acute respiratory symptoms occur.
Current written action plans must be short to be readily used (1 page) and, therefore, cannot fit all acute situations. Moreover, they may not be available where and when required.
The investigators sought that a digital action plan, available through Smartphone or tablet computer connected to the internet, could adequately provide suitable action plans according to the severity of the described exacerbation, and would be more easily available when useful.
The aim of the study is to study the effect of the use of a digital action plan for asthma exacerbation, on the frequency of unscheduled medical contacts (phone calls, visits to physicians or to emergency departments, hospitalizations) in children and in adults with asthma. The investigators hypothesized that the use of the digital action plan could reduce avoidable unscheduled visits due to mild or moderate exacerbations that could successfully be managed by the patient or his/her caregivers.
Detailed description
Asthma is a frequent chronic disease (10% prevalence in children and 7% in adults) during which acute exacerbations can occur that require adequate treatment, usually by the patients and/or his/her caregivers. Despite action plan for asthma exacerbation being recommended by national and international guidelines, urgent medical contact and often Emergency Department visits remain frequent for asthma exacerbation.
Reasons for medical contact may be related to the inefficiency of the current Written Action Plan because of its stereotyped advice whatever the level of severity of the exacerbation, and because the patients might not have the paper with him/her where and when he/she needs it.
The investigators sought that new electronic technologies could solve these issues of inadequacy of content and availability of the Written Action Plan.
A program was built to provide sets of advices according to the severity of the exacerbation described by the patient using simple clinical descriptors included in the Global Initiative for Asthma (GINA), and weighted by the medication already used for the exacerbation. In this way the investigators feel that patients could be more confident in the appropriate treatment proposed by the algorithm. Second, the possibility to connect through portable electronic devices (Smartphone, tablet computer) make the action readily available as far as an internet connection is possible.
The Digital Action Plan is designed to treat asthma exacerbations of all levels of severity and advice to visit a doctor within few days or to go at once to an emergency department as appropriate as by the situation based on the patients' information. The investigators designed a randomized study to assess the effect of the Digital Action Plan on unscheduled urgent medical contacts (phone calls, visits to physicians or to emergency departments, hospitalizations) in children and in adults with asthma.
Methodology of the study A multicenter, controlled, randomized, open study, comparative on 2 parallel groups recruited in private practice and in hospitals within or outside the APHP consortium.
Both arms have the Written Action Plan respecting the current recommendations; the experimental arm has in addition the possibility to connect to the AppWeb to obtain advices from the Digital Action Plan.
The investigators hypothesized that the use of the digital action plan could reduce avoidable unscheduled visits due to mild or moderate exacerbations that could successfully be managed by the patient or his/her caregivers. In the long run, this kind of program could also become a tool for telemedicine Statistical analysis : about 80% of children and adult patients included will have a exacerbation during the follow-up year. The expected effect of the Digital Action Plan is a 20% (relative variation) decrease of the main outcome : in Written Action Plan group, frequency = 0.8, in Digital Action Plan group, frequency = 0.64 (20% i.e. 0.16 reduction of frequency). Moreover, the Written Action Plan has been shown to result in a 25% decrease of unscheduled visits for severe exacerbation (4); we therefore hypothesize that the supplemental reduction in unscheduled visits induced by the Digital Action Plan will be smaller than that of Written Action Plan despite the recording of moderate exacerbations in addition to severe exacerbations. . With this features, samples of N= 121 per group are necessary (80% power, bilateral alpha risk of 5%). With an expected attrition of about 15%, a total of 280 patients will be included. This target can be achieved with regard to the activity of participating centers.
Number of participating centers = 43
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1: Written action plan | Active comparator | Other: Written action planWritten action plan |
| 2: Digital action plan | Experimental | Other: Digital action plan for asthma exacerbations + Written action planWritten action plan + Digital action plan for asthma exacerbations Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation |
Who may qualify
- Ages
- 6 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (8 listed)
- children from 6 to 12 years or adults aged between 18 and 60 years
- typical asthma with medical diagnosis
- severe exacerbation (requiring ≥ 3 days of oral corticosteroids) during the previous 12 months
- Internet connexion through a private (patient's or parents' patient's if child) smartphone and/or a tablet computer
- no use of a written actin plan within the last 1 year
Key exclusion criteria (9 listed)
- atypical asthma: isolated cough, exercise respiratory discomfort
- other respiratory disease (cystic fibrosis, COPD, etc.)
- Severe heart disease (except high blood pressure)
- smoking > 15 pack-years
- asthma requiring regular oral corticosteroids treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Digital action plan for asthma exacerbations + Written action planAlso: Digital action plan for asthma exacerbationsDigital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation | Other | 2: Digital action plan |
| Written action plan | Other | 1: Written action plan |
Primary outcome
Number of visits or unscheduled medical contacts
Time frame: during the 1 year follow-up
Frequency of urgent medical recourses (composite criterion): visits or unscheduled medical contacts + Emergency Departments visits or hospitalizations, in both arms of randomization
Emergency Departments visits or hospitalizations
Time frame: during the 1 year follow-up
Frequency of urgent medical recourses (composite criterion): visits or unscheduled medical contacts + Emergency Departments visits or hospitalizations, in both arms of randomization
10 secondary outcomes
Adherence to the Digital Action Plan = number of moderate to severe exacerbations entered in the AppWeb with respect to all moderate to severe exacerbations reported
Time frame: during the 1 year follow-up
Adherence to the Written Action Plan (number of times Written Action Plan was used with respect to all moderate to severe exacerbations)
Time frame: during the 1 year follow-up
qualitative evaluation of the Digital Action Plan: descriptive study using a questionnaire filled out in the arm using the AppWeb
Time frame: at 1 year
number of unscheduled visits or medical contacts during the 1 year follow-up
Time frame: during the 1 year follow-up
number of visits in Emergency Departments
Time frame: during the 1 year follow-up
number of hospitalizations (>6 hours)
Time frame: during the 1 year follow-up
number of school or working days missed
Time frame: during the 1 year follow-up
number of scheduled medical
Time frame: during the 1 year follow-up
Cumulative dose (in mg/kg) of oral corticosteroids during the 1 year follow-up
Time frame: during the 1 year follow-up
assessment of the level of asthma control (GINA criteria) by a phone call
Time frame: every 3 months, during the 1 year follow-up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2020.
- Derived from this study: PubMed 37255277Beydon N, Taille C, Corvol H, Valcke J, Portal JJ, Plantier L, Mangiapan G, Perisson C, Aubertin G, Hadchouel A, Briend G, Guilleminault L, Neukirch C, Cros P, Appere de Vecchi C, Mahut B, Vicaut E, Delclaux C. Digital Action Plan (Web App) for Managing Asthma Exacerbations: Randomized Controlled Trial. J Med Internet Res. 2023 Jun 29;25:e41490. doi: 10.2196/41490.
- Individual participant dataSharing planned: No
Related trials for Asthma
Enrolling by invitationObservational study
Allergy, Asthma, and Atopic Eczema in Finland
Asthma, Asthma in Children
RecruitingPhase 2
Rademikibart IV for Acute Asthma and COPD Exacerbation
Asthma Acute, COPD Exacerbation Acute
Active, not recruiting
Community Health Equity Accelerator (CHEA) Pediatric Asthma Intervention
Asthma in Children
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
RecruitingObservational study
NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicole BEYDON, MD principal investigator
Assistance Publique - Hôpitaux de Paris
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Digital action plan for asthma exacerbations + Written action plan and Written action plan in people with Asthma, run by Assistance Publique - Hôpitaux de Paris at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of visits or unscheduled medical contacts (time frame: during the 1 year follow-up). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02869958, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2020.